Enveric Biosciences Inc. (ENVB)
1.34
0.00 (0.00%)
Upcoming Events
Latest Headlines
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
June 29, 2026 8:00 AM - BizWire
Enveric Biosciences Announces Participation in 2026 BIO International Convention
June 16, 2026 9:28 AM - BizWire
Form 8-K Enveric Biosciences, For: Jun 09
June 9, 2026 5:17 PM - SEC Filing
Form 424B5 Enveric Biosciences,
June 9, 2026 5:16 PM - SEC Filing
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
June 9, 2026 8:00 AM - BizWire
Form 8-K Enveric Biosciences, For: Jun 08
June 9, 2026 6:02 AM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: Coveney Kevin Michael
June 3, 2026 4:35 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: Tucker Joseph Edward
June 3, 2026 4:33 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: PASQUALONE FRANK
June 3, 2026 4:32 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: WEBB MICHAEL D
June 3, 2026 4:30 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: Schabacker Marcus
June 3, 2026 4:27 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: Kegler George A.
June 3, 2026 4:25 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: DeWitt Sheila
June 3, 2026 4:23 PM - SEC Filing
Form 4 Enveric Biosciences, For: Jun 01 Filed by: Facchini Peter J.
June 3, 2026 4:22 PM - SEC Filing
Enveric Biosciences begins genotoxicity studies for EB-003 drug candidate
June 2, 2026 8:03 AM - StreetInsider
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
June 2, 2026 8:00 AM - BizWire
Form S-8 Enveric Biosciences,
June 1, 2026 6:06 AM - SEC Filing
Form 8-K Enveric Biosciences, For: May 22
May 29, 2026 4:14 PM - SEC Filing
Enveric Biosciences reports no phototoxicity risk for EB-003 candidate
May 19, 2026 8:06 AM - StreetInsider
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026 8:00 AM - BizWire
Form SCHEDULE 13G/A Enveric Biosciences, Filed by: Lind Global Fund III LP
May 15, 2026 4:22 PM - SEC Filing
Form 10-Q Enveric Biosciences, For: Mar 31
May 15, 2026 8:06 AM - SEC Filing
Form 8-K Enveric Biosciences, For: May 15
May 15, 2026 8:01 AM - SEC Filing
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
May 15, 2026 8:00 AM - BizWire
Enveric Biosciences receives US patent for psychiatric treatment methods
May 13, 2026 8:03 AM - StreetInsider
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
May 13, 2026 8:00 AM - BizWire
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026 8:00 AM - BizWire
Form D Enveric Biosciences,
May 4, 2026 4:36 PM - SEC Filing
Form 8-K Enveric Biosciences, For: Apr 30
April 30, 2026 4:03 PM - SEC Filing
Form DEFA14A Enveric Biosciences,
April 30, 2026 4:01 PM - SEC Filing
Form EFFECT Enveric Biosciences,
April 30, 2026 6:16 AM - SEC Filing
Form 424B3 Enveric Biosciences,
April 29, 2026 5:28 PM - SEC Filing
Lakewood-Amedex names Joseph Tucker to board following Nasdaq listing
April 28, 2026 7:33 AM - StreetInsider
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
April 28, 2026 7:33 AM - PR NewsWire
Full Article List
